Ingevity Corporation NGVT
73.00
1.21
1.69%
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 47.4×
Follow NGVT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
48.49 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.23 | 2.13 | 1.84 | 1.91 | |
P/FCF ratio |
16.72 | 10.22 | 7.74 | 8.36 | |
P/Operating CF |
(187.70) | (1,255.68) | 22.08 | 15.45 | |
P/B ratio |
55.23 | 64.56 | 72.18 | 14.51 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.00 | 2.92 | 2.78 | 2.96 | |
EV/EBITDA |
14.65 | 13.66 | 13.19 | 6.27 | |
EV/Operating CF |
16.51 | 11.30 | 9.81 | 10.38 | |
EV/FCF |
22.49 | 13.97 | 11.72 | 12.94 | |
Quick Ratio |
1.00 | 0.81 | 0.60 | 0.61 | |
Current Ratio |
1.61 | 1.42 | 1.33 | 1.27 | |
Net Debt/EBITDA |
10.63 | 9.89 | (23.97) | 9.79 | |
Debt/Assets |
68.70% | 65.59% | 70.34% | 63.17% | |
Debt/Equity |
22.52 | 27.83 | 39.10 | 8.39 | |
Asset Turnover |
0.68 | 0.64 | 0.64 | 0.52 | |
Operating CF/Net income |
(0.39) | (0.03) | (1.15) | 2.98 | |
Capex/Depreciation |
(0.47) | (0.45) | (0.72) | (0.55) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.94% | 2.60% | 2.90% | 2.10% | |
Selling, General and Administrative Expense of Revenue |
12.42% | 15.78% | 16.31% | 13.24% | |
Intangible Assets out of Total Assets |
0.09 | 0.10 | 0.11 | 0.15 | |
Share Based Compensation of Revenue |
1.34% | 1.86% | 1.76% | 1.59% | |
Graham Net Nets |
(0.37) | (0.41) | (0.54) | (0.59) | |
Graham Number |
6.84 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
2.06% | (4.91%) | (7.82%) | (3.26%) | |
Free Cash Flow Yield |
5.98% | 9.79% | 12.93% | 11.96% | |
Revenue per Share |
9.05 | 7.32 | 7.04 | 9.17 | |
Operating CF per Share |
(0.40) | (0.06) | 2.68 | 3.57 | |
Capex per Share |
(0.30) | (0.29) | (0.55) | (0.43) | |
Free Cash Flow per Share |
(0.69) | (0.35) | 2.13 | 3.15 | |
Cash per Share |
5.28 | 5.12 | 2.16 | 2.30 | |
Shareholders Equity per Share |
1.35 | 1.10 | 0.82 | 3.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.35 | 1.10 | 0.82 | 3.80 | |
Free Cash Flow |
(24.10) | (12.30) | 77.10 | 114.20 | |
Working Capital |
206.20 | 172.40 | 112.90 | 110.60 | |
Capital Expenditures |
(10.30) | (10.30) | (20.00) | (15.50) | |
Net Current Asset Value |
(946.80) | (1,029.50) | (1,167.20) | (1,173.50) | |
EV/EBIT |
25.38 | 0.00 | 0.00 | 14.96 | |
Capex to Sales |
0.03 | 0.04 | 0.08 | 0.05 | |
Net Profit Margin |
11.24% | 23.18% | (33.16%) | 13.06% | |
Price to Operating Income |
18.87 | 0.00 | 0.00 | 9.67 | |
| Other line items | |||||
Average Receivables |
174.60 | 157.45 | 129.45 | 179.00 | |
Average Payables |
94.75 | 96.65 | 93.25 | 98.70 | |
Average Inventory |
187.15 | 224.50 | 190.95 | 227.35 | |
Average Assets |
1,707.60 | 1,853.15 | 1,836.85 | 2,022.70 | |
Average Common Equity |
83.80 | 136.75 | 112.45 | 176.30 |
Columns are period end dates